US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The last day of trading with the warrants of series TO5 in PEPTONIC medical AB is today, November 15, 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, November 15, 2024, is the last day of trading with the warrants of series TO5 (“TO5”) in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period for TO5 runs up to and including November 20, 2024. Each TO5 gives the owner the right to

Peptonic Medical AB closes its Israeli subsidiary

Peptonic Medical AB ("Peptonic") today announces its decision to discontinue its Israeli subsidiary, a contract manufacturing organization (CMO) specializing in self-diagnostic tests. The decision will result in significant cost savings. Acquired in 2021 alongside the U.S.-based company Common Sense Marketing Inc. ("Common Sense"), the Israeli manufacturing organization has encountered profitability challenges and increasing operational complexities in Israel. Going forward, Peptonic plans to partner with an external contract manufacturer, while retaining Common Sense as a strategic asset to

The exercise period for subscription of shares through exercise of warrants of series TO5 begins today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, 6 November 2024, the exercise period for warrants of series TO5 (“TO5”) in PEPTONIC medical AB ("Peptonic" or “the Company”) begins. The exercise period runs from and including November 6, 2024, until and including November 20, 2024. Each TO5 entitles

Peptonic Medical strengthens U.S. market presence with full-scale launch of VagiVital

Peptonic Medical AB (publ) ("Peptonic") is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its intimate self-care products. This initiative marks a significant milestone for Peptonic, as the company now assumes full control over brand development, marketing, and sales in the U.S. for the first time. Until now, Peptonic's products have primarily been sold through partners under private labels. With this strategic initiative, Peptonic is positioning itself for a dynamic new phase of growth in the world’s largest healthcare market.Over the

Peptonic Medical launches proprietary lubricant that combines pleasure and care

Peptonic Medical (publ) ("Peptonic") is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically designed to enhance intimate experiences while providing deep hydration. This strategic addition to Peptonic’s growing product portfolio addresses the rising demand for lubricants that combine pleasure with care. In 2022, the global market for personal lubricants was valued at approximately USD 1.2 billion and is expected to experience continued strong growth in the coming years.The personal lubricant

Peptonic announces the last day of trading in BTU and the first day of trading in warrants of series TO 5

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB ("Peptonic” or the "Company") announces that the rights issue which the board of directors resolved on April 16, 2024, and was approved at the annual general meeting

Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038

Peptonic Medical AB (publ) ("Peptonic") has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for Peptonic's self-care product Vernivia, an over-the-counter and antibiotic-free treatment for bacterial vaginosis, as well as the company's mousse-based drug delivery technology Venerol. The patent extends until May 2038, ensuring Vernivia's market exclusivity.Bacterial vaginosis is very common, especially among women of reproductive age, affecting approximately one in three women. Vernivia is the first clinically proven

Peptonic announces outcome in the rights issue and the directed issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB ("Peptonic” or the "Company") has completed the rights issue of units, consisting of shares and warrants of series TO5, which the board of directors resolved on April

Peptonic Medical provides an operational update after the first 120 days with new CEO

Peptonic Medical AB ("Peptonic") today presents an operational update highlighting the strategic measures implemented during Anna Linton's first 120 days as CEO. These efforts, aimed at achieving profitability, combine initiatives for increased sales and cost efficiency.Initiatives for Increased Sales Strategic shift in focus: The company has more clearly shifted its focus towards sales growth. Resources are now more heavily allocated to sales and marketing activities for the existing portfolio of intimate self-care products, while fewer resources are dedicated to the development of

Last day of trading with the unit rights in Peptonic

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, June 7, 2024, is the last day of trading with the unit rights that were issued in conjunction with PEPTONIC medical AB  ("Peptonic” or the "Company") rights issue of units

Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.

Peptonic Medical AB (publ) ("Peptonic") announces that the European Patent Office ("EPO") has granted a patent for the relief of provoked vulvodynia (previously referred to as vestibulitis), effective until April 2041. VagiVital Intimate Calming Gel, the company's proprietary product designed to alleviate the discomfort associated with vulvodynia, will be launched later this year. The product will also be introduced to existing and new international partners for broad distribution.VagiVital Intimate Calming Gel provides immediate soothing and moisturizing effects for vulvodynia and relieves

The subscription period in Peptonic’s rights issue of units starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATIONOF THIS PRESS RELEASE WOULD BE UNLAWFULOR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Today, 28 May, 2024, the subscription period begins in PEPTONIC medical AB (publ) ("Peptonic” or the "Company") rights issue of units consisting of shares and warrants (the "Rights Issue"),

Peptonic publishes prospectus in connection with rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATIONOF THIS PRESS RELEASE WOULD BE UNLAWFULOR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. PEPTONIC medical AB (publ) ("Peptonic” or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of shares and warrants with

Peptonic Medical AB Announces Organizational Changes

Peptonic Medical AB (publ) ("Peptonic") announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their positions in the company.During his time at Peptonic, Erik Sundquist has played a key role in strengthening the company's market position and implementing important business strategies. Erik has decided to focus on other professional projects. Dan Markusson, who has held several significant positions within the company, will be leaving Peptonic in mid-June. "We are grateful for Erik's and Dan's efforts

The board of Peptonic has decided to carry out a directed issue of units consisting of shares and warrants of series TO5

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Peptonic medical AB (publ) ("Peptonic” or the "Company") announces that the board today, with authorization from the annual general meeting on May 24, 2023, has decided to offer all holders of interim shares to participate in a directed issue of a total of 3,

Jenni Björnulfson appointed as new CFO of Peptonic Medical

Peptonic Medical AB (publ) ("Peptonic") announces the appointment of Jenni Björnulfson as the company's new Chief Financial Officer (CFO). Jenni will assume the position on September 1, 2024, replacing Albert Lindgren. During the transition period until Jenni assumes office, Daniel Rudeklint will serve as Acting CFO.Expressing enthusiasm for the appointment, Peptonic’s CEO looks forward to welcoming Jenni to the company. "Jenni brings with her a solid experience in finance and possesses a profound understanding of both public companies and the life science industry. I am confident that her

Warrants of series TO4 were subscribed to approximately 1.80 percent and Peptonic receives approximately SEK 0.1 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. PEPTONIC medical AB ("Peptonic" or the "Company") today announces the outcome of the exercise of warrants of series TO4 (the “Warrants”). In total, 3,538,820 Warrants were exercised, corresponding to approximately 1.80 percent of the total number of outstanding

The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Today, April 26, 2024, is the last day of trading with the warrants of series TO4 (“Warrants”) in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period for the Warrants runs up to and including May 1, 2024. Each Warrant gives the owner the

The board of Peptonic resolves, subject to approval of the general meeting, on a rights issue of units of approximately SEK 61.4 million

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW. Peptonic medical AB (publ) ("Peptonic” or the "Company") announces that the board today, subject to approval of the general meeting, has decided to carry out an issue of units consisting of shares and warrants with preferential rights for existing shareholders

The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024

The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024If all the warrants of series TO4 are exercised, the Company will receive approximately SEK 5.5 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than May 1, 2024, or sell the warrants no later than April 26,2024. Please observe that certain nominees might close their application earlier than May 1, 2024. Summarized terms for the

Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women

Peptonic Medical AB (publ) ("Peptonic") announces that the United States Patent and Trademark Office ("USPTO") has granted patent (16238.0043U1) for the treatment and prevention of vaginal yeast infections among women. The patent, valid until 2041, represents a significant progress for Peptonic in enabling women to independently manage their intimate health. In a clinical study, good treatment results have been demonstrated in a limited group of women.The patent is based on Peptonic's clinically proven gel base which has been adapted to target candida albicans, the most common cause of

Peptonic Medical AB strengthens its position in Europe through an exclusive distribution agreement for VagiVital and Vernivia in the Benelux region

Peptonic Medical AB (publ) ("Peptonic") has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic's products in intimate self-care in Belgium, the Netherlands, and Luxembourg. The products will be distributed under Peptonic's brand, VagiVital and Vernivia. The partnership underscores Peptonic's strategy to expand its geographic presence and strengthen its market position in Europe through collaboration with selected partners. The first order to FirstAid4All will be delivered this week.Peptonic announced today that the company has signed an exclusive distribution

Peptonic Medical AB announces that CFO is leaving for new challenges and that the company's financial infrastructure is strengthened

Peptonic Medical AB (publ) ("Peptonic") today announces that CFO, Albert Lindgren, is leaving the company to take on new challenges. Albert is expected to remain with Peptonic until mid-June when he goes on parental leave.In connection with the recruitment of a new CFO, Peptonic will restructure and strengthen its finance department to fully manage the company's finances internally. The initiative reflects Peptonic's ambition to evolve into a global company, where a robust financial infrastructure with broad expertise is crucial for creating tailored solutions for various parts of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe